Home › Certara's Synchrogenix Division Provides Unique Technology Solution, Enabling Biopharma Companies To Comply With EMA Policy 70
 

Keywords :   


Certara's Synchrogenix Division Provides Unique Technology Solution, Enabling Biopharma Companies To Comply With EMA Policy 70

2016-03-30 06:49:06| drugdiscoveryonline Home Page

Certara, the global biosimulation technology-enabled drug development company, recently announced that its regulatory and medical consultancy, Synchrogenix, has introduced an artificial intelligence (AI) -enabled solution to meet the data transparency requirements of the clinical and drug development market

Tags: policy technology unique companies

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
22.11Spain fines budget airlines including Ryanair 179m
22.11Eastern North Pacific Tropical Weather Outlook
22.11Atlantic Tropical Weather Outlook
22.11Rush PANTS
22.11SBS
22.11/
22.11 YOU
22.11
More »